New prescribing advice for Protelos

A review into the safety of strontium ranelate (Protelos) with regard to venous thromboembolism (VTE) and serious skin reactions has been completed by the EMA.

Osteoporosis is caused by an imbalance between bone resorption (shown here) and bone formation | SCIENCE PHOTO LIBRARY
Osteoporosis is caused by an imbalance between bone resorption (shown here) and bone formation | SCIENCE PHOTO LIBRARY

The agency has recommended that the postmenopausal osteoporosis treatment not be prescribed to patients with VTE or a history of VTE, or to patients who are temporarily or permanently immobilised. Since the risk of VTE is also increased in the elderly, prescribers should re-evaluate the need for continued treatment with strontium ranelate in patients over 80 years of age.

Patients must stop treatment immediately if a severe allergic reaction occurs, such as skin rash, and treatment should not be reinitiated.

Patients should be made aware of the timings and symptoms of potential serious skin reactions to strontium ranelate, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS). The risk of SJS and TEN is highest within the first few weeks of treatment; DRESS occurs most commonly after around 3–6 weeks of treatment.

View Protelos drug record

Further information: Servier Laboratories Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Protelos: EMA recommends further restrictions for use

Protelos: EMA recommends further restrictions for use

The use of Protelos (strontium ranelate) for the treatment...

MHRA restricts Protelos indications and adds new cardiovascular warnings

MHRA restricts Protelos indications and adds new cardiovascular warnings

In light of cardiovascular safety concerns, the MHRA...

Protelos approved for osteoporosis in men

Protelos approved for osteoporosis in men

Protelos (strontium ranelate) can now be used to treat...

Protelos safety update

The MHRA has issued advice stating that women taking...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases